Latvia Antihypertensive Medicine Sales is set to reach $5.3 Million by 2026 from $4.84 Million, will grow 4.4% per year. Italy, Spain and Australia respectively ranked numbers 2, 3 and 4 in this ranking.
How does Latvia perform in Antihypertensive?
Forecast: Renin-Angiotensin System Medicine Sales in Latvia
- Million US Dollars PPP
- 2024 to 2028
- ReportLinker Research
Forecast: Renin-Angiotensin System Medicine Sales in Latvia
- Percent of Total Sales
- 2024 to 2028
- ReportLinker Research
Forecast: Antihypertensive Medicine Sales in Latvia
- Million US Dollars PPP
- 2024 to 2028
- ReportLinker Research
Forecast: Renin-Angiotensin System Medicine Sales in Latvia
- US Dollars PPP Per Capita
- 2024 to 2028
- ReportLinker Research
Forecast: Antihypertensive Medicine Use in Latvia
- Units (Defined Daily Dosage) Per Thousand Persons Per Day
- 2024 to 2028
- ReportLinker Research
Forecast: Antihypertensive Medicine Sales in Latvia
- US Dollars Per Capita
- 2024 to 2028
- ReportLinker Research
Forecast: Renin-Angiotensin System Medicine Sales in Latvia
- Million Euros
- 2024 to 2028
- ReportLinker Research
Forecast: Antihypertensive Medicine Sales in Latvia
- Million Euros
- 2024 to 2028
- ReportLinker Research
Forecast: Antihypertensive Medicine Sales in Latvia
- Percent of Total Sales
- 2024 to 2028
- ReportLinker Research
Forecast: Renin-Angiotensin System Medicine Sales in Latvia
- US Dollars Per Capita
- 2024 to 2028
- ReportLinker Research